BioPharma Dive January 13, 2026
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.
SAN FRANCISCO — Many biopharmaceutical industry deals begin in a meeting room during the annual J.P. Morgan Healthcare conference.
Startups lean into networking events and one-on-one conversations, hoping to attract investor interest and pharma partners that can provide cash and needed help bringing their experimental drugs forward.
Those conversations may be more fruitful for young biotechnology firms this year. A report published last week by HSBC Innovation Banking showed that biotech venture investments surged in the fourth quarter to their highest totals in three years. During that period, investors shifted from a “conversative” mindset to embracing the chance...
Today's Sponsors
Today's Sponsor